Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.

Rincon MY, de Vin F, Duqué SI, Fripont S, Castaldo SA, Bouhuijzen-Wenger J, Holt MG.

Gene Ther. 2018 Apr;25(2):83-92. doi: 10.1038/s41434-018-0005-z. Epub 2018 Mar 9.

PMID:
29523880
2.

Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.

Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, Okada Y, Hirai H.

Neurosci Lett. 2018 Feb 5;665:182-188. doi: 10.1016/j.neulet.2017.11.049. Epub 2017 Nov 24.

PMID:
29175632
3.

Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.

Hammond SL, Leek AN, Richman EH, Tjalkens RB.

PLoS One. 2017 Dec 15;12(12):e0188830. doi: 10.1371/journal.pone.0188830. eCollection 2017.

4.

Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection.

McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, Isacson O.

Neurosci Lett. 2014 Jul 25;576:73-8. doi: 10.1016/j.neulet.2014.05.044. Epub 2014 May 29.

5.

More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B.

Dayton RD, Grames MS, Klein RL.

Gene Ther. 2018 Aug;25(5):392-400. doi: 10.1038/s41434-018-0028-5. Epub 2018 Jul 16.

PMID:
30013186
6.

Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK.

Nat Biotechnol. 2009 Jan;27(1):59-65. doi: 10.1038/nbt.1515. Epub 2008 Dec 21.

7.
8.

Glial promoter selectivity following AAV-delivery to the immature brain.

von Jonquieres G, Mersmann N, Klugmann CB, Harasta AE, Lutz B, Teahan O, Housley GD, Fröhlich D, Krämer-Albers EM, Klugmann M.

PLoS One. 2013 Jun 14;8(6):e65646. doi: 10.1371/journal.pone.0065646. Print 2013.

9.

Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord.

Dirren E, Towne CL, Setola V, Redmond DE Jr, Schneider BL, Aebischer P.

Hum Gene Ther. 2014 Feb;25(2):109-20. doi: 10.1089/hum.2013.021. Epub 2014 Jan 15.

PMID:
24191919
10.

Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice.

Gholizadeh S, Tharmalingam S, Macaldaz ME, Hampson DR.

Hum Gene Ther Methods. 2013 Aug;24(4):205-13. doi: 10.1089/hgtb.2013.076. Epub 2013 Aug 3.

11.

A Single Vector Platform for High-Level Gene Transduction of Central Neurons: Adeno-Associated Virus Vector Equipped with the Tet-Off System.

Sohn J, Takahashi M, Okamoto S, Ishida Y, Furuta T, Hioki H.

PLoS One. 2017 Jan 6;12(1):e0169611. doi: 10.1371/journal.pone.0169611. eCollection 2017.

12.
13.

Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.

Jayandharan GR, Zhong L, Sack BK, Rivers AE, Li M, Li B, Herzog RW, Srivastava A.

Hum Gene Ther. 2010 Mar;21(3):271-83. doi: 10.1089/hum.2009.100.

14.
15.

Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Bey K, Ciron C, Dubreil L, Deniaud J, Ledevin M, Cristini J, Blouin V, Aubourg P, Colle MA.

Gene Ther. 2017 May;24(5):325-332. doi: 10.1038/gt.2017.18. Epub 2017 Apr 20.

PMID:
28425480
16.

Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B.

Jackson KL, Dayton RD, Deverman BE, Klein RL.

Front Mol Neurosci. 2016 Nov 4;9:116. eCollection 2016. Erratum in: Front Mol Neurosci. 2016 Dec 22;9:154.

17.

Improved gene delivery to adult mouse spinal cord through the use of engineered hybrid adeno-associated viral serotypes.

Siu JJ, Queen NJ, Huang W, Yin FQ, Liu X, Wang C, McTigue DM, Cao L.

Gene Ther. 2017 Jun;24(6):361-369. doi: 10.1038/gt.2017.27. Epub 2017 Apr 25.

18.

Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington's disease mice.

Vagner T, Dvorzhak A, Wójtowicz AM, Harms C, Grantyn R.

Mol Cell Neurosci. 2016 Dec;77:76-86. doi: 10.1016/j.mcn.2016.10.007. Epub 2016 Oct 27.

PMID:
27989734
19.

AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy.

Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M, Cabassi T, Cattaneo S, Luoni M, Cancellieri C, Sessa A, Bacigaluppi M, Taverna S, Leocani L, Lanciego JL, Broccoli V.

Mol Ther. 2017 Dec 6;25(12):2727-2742. doi: 10.1016/j.ymthe.2017.08.004. Epub 2017 Aug 10.

20.

Efficient retrograde neuronal transduction utilizing self-complementary AAV1.

Hollis ER 2nd, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH.

Mol Ther. 2008 Feb;16(2):296-301. doi: 10.1038/sj.mt.6300367. Epub 2007 Nov 27.

Supplemental Content

Support Center